Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy
Reuters
Dec 01
<a href="https://laohu8.com/S/CMND">Clearmind Medicine</a> Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy
Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder (AUD). The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594388-en) on December 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.